Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Pediatrics

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy

  • Nagendra Chaudhary1, 2Email author,
  • Madhulika Kabra3,
  • Sheffali Gulati4,
  • Yogendra Kumar Gupta5,
  • Ravindra Mohan Pandey6 and
  • Bal Dev Bhatia2
Contributed equally
BMC PediatricsBMC series – open, inclusive and trusted201616:66

https://doi.org/10.1186/s12887-016-0603-0

Received: 1 May 2015

Accepted: 11 May 2016

Published: 14 May 2016

Abstract

Background

Phenytoin, mainly metabolized by cytochrome P450 enzyme system, has a narrow therapeutic index and may have adverse effects due to inter-individual variation in the dose requirement and genetic polymorphisms. This cross-sectional study was done to study the prevalence of cytochrome P450 CYP2C9 polymorphisms in Indian epileptic children and to see the effect of polymorphisms on serum levels in epileptic children on phenytoin monotherapy.

Methods

We studied 89 epileptic children of North Indian population, randomly selected, to see the genotypic and allelic frequency of CYP2C9 and its association with drug levels on phenytoin monotherapy. Analysis was done using STATA 9 Software. The results were analyzed as prevalence at 95 % C.I. (Confidence Interval). The difference in mean phenytoin serum levels between wild and mutant alleles was tested using Student`s T test for independent samples. P value less than 0.05 was considered statistically significant.

Results

CYP2C9*1, *2 & *3 allelic frequencies were 85.4, 4.5 and 10.1 % respectively. CYP2C9*3 allelic group showed significantly higher serum phenytoin levels compared to the wild variants (P = 0.009). There was no statistically significant difference in the dose received (P = 0.12) and side effects of CYP2C9*2 and CYP2C9*3 genotypes (P = 0.442 and 0.597 respectively) when compared with wild variant.

Conclusion

CYP2C9*3 is more common than *2 in the present study. All the polymorphisms demonstrated in our study were heterozygous with no homozygosity. Serum phenytoin levels are higher in polymorphic groups (*3) which suggest their poor metabolizing nature. Genotyping may help to avoid toxicity and concentration-dependent adverse effects.

Keywords

EpilepsyNeurocysticercosisCYP2C9 polymorphismPhenytoin monotherapy

Background

Epilepsy is a common disorder in pediatric practice, with a prevalence of 5.59 per 1000 population with no gender or geographical differences in Indian population [1]. Phenytoin is one of the commonly prescribed drugs in children for seizure control. CYP2C9 may be involved in 80–90 % of metabolism of phenytoin and therefore polymorphisms in CYP2C9 may result in significant reduction in the metabolism of phenytoin and can enhance clinical toxicity of the drug [24]. CYP2C9 gene is located on the long arm of chromosome 10 at 10q24, has 10 exons and 1847 bases coding DNA which codes for 490 amino acid protein. CYP2C9*2 polymorphism results due to c.430C > T nucleotide change resulting in p.Arg144Cys amino acid change (rs#1799853) whereas CYP2C9*3 results due to change in c.1075A > C resulting in p.Ile359leu amino acid change (rs#1057910). CYP2C9*1 allelic groups have normal enzyme activity whereas the CYP2C9*2 (Cys 144) allelic groups have reduced enzyme activity, and even lower activity in CYP2C9*3 (Leu359) variants. In Caucasians, the most common variant of CYP2C9 is CYP2C9*2 (10–13 % of the population), whereas the frequency of CYP2C9*3 varies from 5–9 % [57]. In Asians and Africans, these two alleles appear at lower frequency than seen in the Caucasians [8]. In Chinese and Japanese, the CYP2C9*2 allele has not been detected [911]. Previous genotyping reports in different ethnic groups in India demonstrate wide differences in the distribution of the CYP2C9 alleles.

Methods

Baseline characteristics

This is a cross-sectional observational study done between June 2010 to May 2012, where 89 epileptic children (Males:55, Females: 34) of North Indian origin between age groups 5–12 years with mean age 9.29 (±2.7) years on phenytoin were finally included for analysis (Fig. 1). Sample size was calculated by anticipating 50 % prevalence of cytochrome P450 CYP2C9 in epilepsy patients to fall within 10 % points of the true proportion with 95 % confidence [12]. Cases were enrolled from Out-patient department and Neurocysticercosis Clinic of All India Institute of Medical Sciences. Majority (93.3 %) of cases included were of neurocysticercosis while rest were having Idiopathic epilepsy (6.7 %). These patients were on phenytoin monotherapy for at least 1 month or more [Mean duration: 12.7 months, Median (min, max): 7 (1–78) months] and were on same drug regimen at the time of drug level measurement. Doses were adjusted once the phenytoin level was >20 mcg/ml. None of the children under study had hepatic or renal dysfunction. Children on polytherapy (more than one antiepileptic drugs), those with genetic syndromes and on drugs that interfere with the metabolism of phenytoin were excluded. Informed written consent was obtained from parents. The study was approved by the Institute`s ethics committee (Office of ethics subcommittee, All India Institute of Medical Sciences, Room no 102, 1st floor, Old OT block, Ansari Nagar, New Delhi-110029, Ref No: IESC/T-182/2010).
Fig. 1

Work plan for the study

DNA extraction and genotyping

CYP2C9*2 which codes for amino acid change Arg144Cys was detected by PCR-RFLP as described [13] using the following primers; [Forward primer: 5′-cac tgg ctg aaa gag cta aca gag-3′ (24 bases) and Reverse primer: 5′-gtg ata tgg agt agg gtc acc cac-3′ (24 bases)], to amplify a 375 bp amplicon in a 25 μL PCR mix comprising 2.5 μL 10X buffer, 2.5 μL of 2 mM dNTPs, 1 μL of 10 μM each forward and reverse primers, 0.25 μL Taq polymerase, 100.5 μL of sterile water and 1 μL of 100 ng/μL genomic DNA. PCR methodology has been explained in Additional file 1.

Unrestricted PCR products were of 375 bp. After restriction digestion, homozygote TT samples at c.430 gave 375 bp only (similar to unrestricted PCR products) whereas heterozygotes (CT samples) gave 375 bp, 297 bp and 78 bp products. Homozygote CC samples gave 297 bp and 78 bp products only (Fig. 2).
Fig. 2

Electrophoresis on 2 % agarose gel after digestion with Ava II (Abbreviations: bp-base pairs). Lanes 1–8, 12–18, 20: *1/*2. Lanes 11 and 19: *1/*2. Lane 9: 100 bp ladder. Lane 10: Unrestricted PCR product

CYP2C9*3 which is responsible for amino acid change Ile359Leu was detected by PCR-RFLP assay [13] using following primers: Forward primer: 5′-agg aag aga ttg aac gtg tga-3′ (21 bases) and Reverse primer: 5′-ggc agg ctg gtg ggg aga agg cca a-3′ (25 bases). PCR conditions were the same as described (Additional file 1). Unrestricted PCR products were of 130 bp. After restriction digestion, homozygote AA samples at c.1075 gave 130 bp only (similar to unrestricted PCR products) whereas heterozygotes (AC samples) gave 130 bp, 104 bp and 26 bp products. Homozygote CC samples gave 104 bp and 26 bp products only (Fig. 3).
Fig. 3

Electrophoresis on 3 % agarose gel after digestion with Sty I (Abbreviations: bp- base pairs). Lanes 1, 5, 10, 14, 18: *1/*3. Lanes 2–4, 6–9, 11–13, 15–17 and 19: *1/*1. Lane 20: Unrestricted PCR product

Phenytoin estimation

2–3 ml blood sample was collected in plain vial the next morning after giving the evening dose of phenytoin. The sample was centrifuged immediately at 10,000 RPM for 10 min. The separated serum was then transferred to micro-centrifuge tubes and stored at −80 °C till phenytoin levels was estimated. Phenytoin level in serum was estimated by High Performance Liquid Chromatography (HPLC). Shimadzu (Prominence) HPLC equipment with Photo Diode Array Detector (PDA) was used at 210 nm. Agilent Zorbax SB-C18 column was used. Flow rate was at 1.2 ml/min. The mobile phase consisted of following ingredients: Potassium dihydrogen orthophosphate buffer (50 mM): Acetonitrile: Methanol 58:21:21 (v/v/v). The mobile phase was filtered through 0.22 μm membrane filter and degassed prior to use. 200 μl of serum was then vortexed mixed with 20 μl diazepam (3 mg/ml) as internal standard, then again it was vortexed and mixed with 200 μl acetonitrile (HPLC grade) for 1 min. The mixture was centrifuged at 15000 rpm for 12 min and the supernatant was separated. 25 μl of the supernatant was filtered through a 0.4 μM filter and was directly injected into the HPLC system. Patient samples were estimated for phenytoin levels by using a standard calibration curve.

Statistical analysis

Genotype frequencies in the study population were checked for Hardy-Weinberg equilibrium. Analysis was done using STATA 9 Software. The results were analyzed as prevalence at 95 % C.I. (confidence Interval). The difference in mean phenytoin serum levels between wild and mutant alleles was tested using Student’s T test for independent samples. P value less than 0.05 was considered statistically significant.

Results

The frequency of CYP2C9*1/*2/*3 alleles were 85.4, 4.5 and 10.1 % respectively. The frequency for *1/*1, *1/*2, *1/*3 and *2/*3 genotypes was 71.9, 7.9 , 19.1 % and 1.1 % respectively (Table 1). A single individual was heterozygous for both *2 and *3 polymorphism. CYP2C9*2 genotyping showed 91 % to be wild (CC) and 9 % were heterozygous (CT). No homozygous polymorphism was identified in this study population as expected from the Hardy Weinberg equilibrium. The frequency of wild alleles (C) was 95.5 % and the mutant allele (T) was 4.5 % (Table 2). Genotyping for CYP2C9*3 showed prevalence of 79.8 % for the wild (AA) and 20.2 % for the mutant group (AC). Allele distribution was 89.9 % for the wild and 10.1 % for the mutant. All of the polymorphisms detected were heterozygous. No homozygosity was identified (Table 3). The means for phenytoin doses required in the CC and CT groups did not vary significantly, neither the difference in phenytoin levels in these two groups was significant (Table 4). The mean doses (mg/kg) in AA and AC groups were 5.3 and 4.8 with no statistically significant results but the median phenytoin levels compared in both the groups were statistically significant (P = 0.009) (Table 5). The frequency of side effects (gum hypertrophy, ataxia, hirsuitism) in both the polymorphic groups was not statistically significant (P = 0.442 and 0.597 for *2 and *3 genotypes) (Table 6).
Table 1

CYP2C9 alleles and genotypes

CYP2C9 allele and genotype

CYP2C9 allele frequencies (n = 89)

95 % Confidence interval (%)

CYP2C9*1

85.4 %

80.21–90.59

CYP2C9*2

4.5 %

1.45–7.55

CYP2C9*3

10.1 %

5.67–14.53

CYP2C9*1/*1

71.9 %

62.56–81.24

CYP2C9*1/*2

7.9 %

2.27–13.45

CYP2C9*1/*3

19.1 %

10.93–27.27

CYP2C9*2/*3

1.1 %

0–3.27

CYP2C9*2/*2

0 %

0

CYP2C9*3/*3

0 %

0

Table 2

Genotypes and alleles of CYP2C9*2 with prevalence and 95 % CI

CYP2C9*2 genotypes

Number (n = 89)

Prevalence (%)

95 % CI

CC

81

91

83–96

CT

8

9

3–16

Alleles

No of Alleles

Frequency

95 % CI

C

170

95.5

91–98

T

8

4.5

1.9–8

Table 3

Genotypes and alleles of CYP2C9*3 with prevalence and 95 % CI

CYP2C9*3 genotypes

Number (n = 89)

Prevalence (%)

95 % CI

AA

71

79.8

69–87

AC

18

20.2

12–30

Alleles

No of Alleles

Frequency

95 % CI

A

160

89.9

84–94

C

18

10.1

6–15

Table 4

Comparing wild and mutant genotypes of CYP2C9*2 for dose (mg/kg) and drug level (mcg/ml)

Variables

CC (n = 81)

CT (n = 8)

P value

Dose (mean ± SD)

5.2 ± 1.15

5.1 ± 0.95

0.89

Phenytoin levela (median)

6.8

9.5

0.74

aNon parametric test applied as variability was high (Wilcoxon rank-sum test)

Table 5

Comparing wild and mutant genotypes of CYP2C9*3 for dose (mg/kg) and drug level (mcg/ml)

Variables

AA (n = 71)

AC (n = 18)

P value

Dose (mean ± SD)

5.3 ± 1.20

4.8 ± 0.69

0.12

Phenytoin levela (Median)

5.9

18.8

0.009

aNon parametric test applied as variability was high (Wilcoxon rank-sum test)

Table 6

Percentage of side effects in *2 and *3 groups

 

Side effects

P value

Gum hypertrophy

Hirsuitism

Ataxia

Yes

No

CYP2C9*2 genotypes

      

CC

5 (5.6 %)

76 (85.4 %)

0.442

4 (4.5 %)

0

1 (1.1 %)

CT

1 (1.1 %)

7 (7.9 %)

1 (1.1 %)

1 (1.1 %)

0

CYP2C9*3 genotypes

      

AA

4 (4.5 %)

67 (75.3 %)

0.597

4 (4.5 %)

1 (1.1 %)

0

AC

2 (2.2 %)

16 (18.0 %)

1 (1.1 %)

0

1 (1.1 %)

Discussion

The frequency of *2 alleles in our study was 0.045 which is less than the reported in Italian, Greek, Russian, Swedish and Iranian Population. Frequency of *3 in our study population was higher than in Chinese, Japanese, Americans, Russian, and Swedish (Table 7). CYP2C9*2 genotypes are negligible or almost absent in the Chinese and Japanese [810] while Caucasians have higher frequencies of *2 as compared to *3 genotypes [6, 9, 14]. CYP2C9*3 alleles in the Italian and our population was almost similar. The frequencies of CYP2C9 genotypes are given in Table 5.
Table 7

Comparison of CYP2C9 (*1, *2, *3) in different population in relation to the North Indian population

Ethnicity

Number

*1

*2

*3

Chinese Han [9]

196

0.974

0

0.026

African American [9]

200

0.985

0.010

0.005

European American [9]

200

0.860

0.080

0.060

Japanese [10]

436

0.979

0

0.021

Sweden [26]

430

0.819

0.107

0.074

Egypt [7]

247

0.817

0.118

0.062

Russian [6]

290

0.827

0.105

0.067

Italian [27]

360

0.777

0.125

0.097

UK [14]

297

0.841

0.106

0.052

Japan [8]

828

0.976

0

0.023

Greek [5]

283

0.79

0.128

0.081

Iran [28]

200

0.873

0.127

0

Italian [29]

150

0.648

0.253

0.098

Chinese Mongolian [11]

560

0.970

0

0.030

Indian Studies

Ethnicity

Number

*1

*2

*3

Tamilian population [15]

135

0.9

0.03

0.07

South Indian population [16]

346

0.88

0.04

0.08

Northern Indian population [17]

102

0.95

0.049

0.039

Present study in North Indian population (Delhi)

89

0.85

0.045

0.10

The frequencies of CYP2C9*2 in Indian population have found to be between 3–5 % whereas CYP2C9*3 ranges from 4–8 % [1517]. The allele frequencies of *2 and *3 in Indian population published till date were found to be almost similar to the present study. A study done in North Indian population by Rathore et al. revealed similar *2 allelic frequencies with lower *3 allelic frequencies (0.10 Vs 0.039). Most of these studies have been carried out on smaller sample size. Our study also had a small sample size. Therefore, multi-centric studies with large sample size should be carried out to solve these discrepancies of the allelic frequency in different studies in the same population.

We also studied association of the CYP2C9*2 and *3 polymorphisms with phenytoin levels. The median phenytoin levels (mcg/ml) in the *2 genotypes, both wild (CC) and mutant (CT) was 6.8 and 9.5 respectively (not significant). We generally use phenytoin at the dose of 5–8 mg/kg/day and maintain a drug level between 10–20 mcg/ml at our center. Statistically significant difference in the drug levels between the CYP2C9*3 wild and mutant genotypes (P = 0.009) was observed in our study suggesting the poor metabolizing nature in polymorphic groups; although there was no significant toxicity in those groups.

Recent pharmacogenetic studies have demonstrated the importance of polymorphism with phenytoin levels [13, 1820]. In a recent study by Vander Weide et al. demonstrated that patients with at least one mutant CYP2C9 allele required a lower dose of phenytoin to achieve a therapeutic serum drug concentration than did the patients with two normal alleles [21]. Lee at al also demonstrated that CYP2C9*3 variants in Korean patients had higher propensity to develop phenytoin induced cutaneous adverse reactions [22]. Kesavan et al. also demonstrated a higher phenytoin levels and toxicity in CYP2C9*2 and CYP2C9*3 allelic variants [23].

Similarly the mean serum concentration of phenytoin of the polymorphic patients with epilepsy was higher than that for the wild-type alleles both in the monotherapy and polytherapy patients in a study done by Ozkaynakci A et al. [24].

In a recent study done by Yamamoto Y et al. concluded that genotyping could help in estimating the optimum target dose of phenytoin and may contribute to avoid toxicity and concentration-dependent adverse effects [25]. These results show the importance of the genetic polymorphism analysis of the main metabolizing enzyme groups of phenytoin for the dose adjustment.

Conclusions

In summary, both the *2 and *3 allelic variants are commonly seen in the Indian population with CYP2C9*3 being more common than *2 in the present study. All the polymorphisms demonstrated in our study were heterozygous. No homozygosity was seen in our study which suggests that the homozygous polymorphism is rare in this population. The frequency of polymorphism has been found to be different in different population in India itself and some studies in the same population has shown conflicting results which can be solved by conducting larger multi-centric studies. Although *3 group had significantly higher serum phenytoin level when compared to *1 group, they did not have significantly higher toxicity. As the number of patients with toxicity in our study was small, no further conclusive recommendations could be made for clinical implications. Genotyping of the CYP2C9 gene in patients on antiepileptic drugs (eg. Phenytoin) may help to overcome the drug toxicity, choose the right molecule and guide in therapeutic drug monitoring.

Ethics

The study was approved by the Institute’s ethics committee (Office of ethics subcommittee, All India Institute of Medical Sciences, Room no 102, 1st floor, Old OT block, Ansari Nagar, New Delhi-110029, Ref No: IESC/T-182/2010).

Consent to participate

Informed and written consent was taken to participate in the study.

Consent to publish

Consent to publish was obtained from the parents.

Availability of data and materials

Data has been provided in the materials and methods section of the manuscript. If required, individual data can be obtained from Genetic unit, Department of Pediatrics, All India institute of medical Sciences, New Delhi, India.

Abbreviations

bp: 

base pair

CI: 

confidence interval

CYP: 

cytochrome P 450

HPLC: 

high performance liquid chromatography

mcg: 

microgram

ml: 

milliliters

PCR: 

polymerase chain reaction

RFLP: 

restriction fragment length polymorphism

Declarations

Acknowledgements

The authors acknowledge the Department of Pediatrics, Division of genetics, All India Institute of Medical Sciences, New Delhi for providing support and technical help in the study. We thank Mr. Shivaram Shastri, Scientist, Genetics Unit, All India Institute of Medical Sciences for constant guidance/technical support throughout the study. The authors also thank Dr Thomas, Scientist, Department of Pharmacology, All India Institute of Medical Sciences for helping in phenytoin estimation procedure.

Funding

None.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Pediatrics, All India Institute of Medical Sciences
(2)
Department of Pediatrics, Universal College of Medical Sciences
(3)
Genetic Unit, Department of Pediatrics, All India Institute of Medical Sciences
(4)
Division of Pediatric Neurology, Department of Pediatrics, All India Institute of Medical Sciences
(5)
Department of Pharmacology, All India Institute of Medical Sciences
(6)
Department of Biostatistics, All India Institute of Medical Sciences

References

  1. Sridharan R, Murthy BN. Prevalence and pattern of epilepsy in India. Epilepsia. 1999;40(5):631–6.View ArticlePubMedGoogle Scholar
  2. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001;52(4):349–55.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics. 2000;10(2):95–104.View ArticlePubMedGoogle Scholar
  4. Rettie AE, Haining RL, Bajpai M, Levy RH. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res. 1999;35(3):253–5.View ArticlePubMedGoogle Scholar
  5. Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavridou A, et al. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol. 2007;21(4):419–26.View ArticlePubMedGoogle Scholar
  6. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmöller J, Frötschl R, Köpke K, et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol. 2003;59(4):303–12.View ArticlePubMedGoogle Scholar
  7. Hamdy SI, Hiratsuka M, Narahara K, El-Enany M, Moursi N, Ahmed MS-E, et al. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol. 2002;53(6):596–603.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Mushiroda T, Ohnishi Y, Saito S, Takahashi A, Kikuchi Y, Saito S, et al. Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. J Hum Genet. 2006;51(3):249–53.View ArticlePubMedGoogle Scholar
  9. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 1996;6(4):341–9.View ArticlePubMedGoogle Scholar
  10. Nasu K, Kubota T, Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics. 1997;7(5):405–9.View ArticlePubMedGoogle Scholar
  11. Yang L, Ge W, Yu F, Zhu H. Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement--a systematic review and meta analysis. Thromb Res. 2010;125(4):e159–66.View ArticlePubMedGoogle Scholar
  12. Rosemary J, Surendiran A, Rajan S, Shashindran CH, Adithan C. Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India. Indian J Med Res. 2006;123(5):665–70.PubMedGoogle Scholar
  13. Aynacioglu AS, Brockmöller J, Bauer S, Sachse C, Güzelbey P, Ongen Z, et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol. 1999;48(3):409–15.View ArticlePubMedGoogle Scholar
  14. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106(7):2329–33.View ArticlePubMedGoogle Scholar
  15. Adithan C, Gerard N, Naveen AT, Koumaravelou K, Shashindran CH, Krishnamoorthy R. Genotype and allele frequency of CYP2D6 in Tamilian population. Eur J Clin Pharmacol. 2003;59(7):517–20.View ArticlePubMedGoogle Scholar
  16. Jose R, Chandrasekaran A, Sam SS, Gerard N, Chanolean S, Abraham BK, et al. CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population. Fundam Clin Pharmacol. 2005;19(1):101–5.View ArticlePubMedGoogle Scholar
  17. Rathore SS, Agarwal SK, Pande S, Mittal T, Mittal B. Frequencies of VKORC1 -1639 G>A, CYP2C9*2 and CYP2C9*3 genetic variants in the Northern Indian population. Biosci Trends. 2010;4(6):333–7.PubMedGoogle Scholar
  18. Hashimoto Y, Otsuki Y, Odani A, Takano M, Hattori H, Furusho K, et al. Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Biol Pharm Bull. 1996;19(8):1103–5.View ArticlePubMedGoogle Scholar
  19. Mamiya K, Ieiri I, Shimamoto J, Yukawa E, Imai J, Ninomiya H, et al. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia. 1998;39(12):1317–23.View ArticlePubMedGoogle Scholar
  20. Odani A, Hashimoto Y, Otsuki Y, Uwai Y, Hattori H, Furusho K, et al. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharmacol Ther. 1997;62(3):287–92.View ArticlePubMedGoogle Scholar
  21. van der Weide J, Steijns LS, van Weelden MJ, de Haan K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics. 2001;11(4):287–91.View ArticlePubMedGoogle Scholar
  22. Lee A-Y, Kim M-J, Chey W-Y, Choi J, Kim B-G. Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions. Eur J Clin Pharmacol. 2004;60(3):155–9.View ArticlePubMedGoogle Scholar
  23. Kesavan R, Narayan SK, Adithan C. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients. Eur J Clin Pharmacol. 2010;66(7):689–96.View ArticlePubMedGoogle Scholar
  24. Ozkaynakci A, Gulcebi MI, Ergeç D, Ulucan K, Uzan M, Ozkara C, et al. The effect of polymorphic metabolism enzymes on serum phenytoin level. Neurol Sci. 2015;36(3):397–401.View ArticlePubMedGoogle Scholar
  25. Yamamoto Y, Takahashi Y, Imai K, Miyakawa K, Ikeda H, Ueda Y, et al. Individualized Phenytoin Therapy for Japanese Pediatric Patients With Epilepsy Based on CYP2C9 and CYP2C19 Genotypes. Ther Drug Monit. 2015;37(2):229–35.View ArticlePubMedGoogle Scholar
  26. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjöqvist F. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun. 1999;254(3):628–31.View ArticlePubMedGoogle Scholar
  27. Scordo MG, Caputi AP, D’Arrigo C, Fava G, Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res. 2004;50(2):195–200.View ArticlePubMedGoogle Scholar
  28. Zand N, Tajik N, Moghaddam AS, Milanian I. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. Clin Exp Pharmacol Physiol. 2007;34(1–2):102–5.View ArticlePubMedGoogle Scholar
  29. Azarpira N, Namazi S, Hendijani F, Banan M, Darai M. Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran. Pharmacol Rep. 2010;62(4):740–6.View ArticlePubMedGoogle Scholar

Copyright

© Chaudhary et al. 2016

Advertisement